Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab…
Now that we've got the bad news out of the way, we're here to spread…
Genmab has achieved $1B sales in the US of its blood cancer drug, Darzalex, setting a…
The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow…
What are the most impressive advances in medical biotechnology this year? From cancer to peanut…
From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year's…
PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma…
Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T…
Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some…
Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück…
Today is the World Blood Cancer Day, an event to show solidarity to patients and…